Anika Therapeutics Inc (ANIK)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Anika Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 20.70 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 1.0%
- Exp. sales growth 3Y > 5% 6.8%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 6.8%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 6
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -8.1%
- ROCE > 15% -6.6%
- Expected return > 10% 8.5%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -10.3% failed
- More than 10% revenue growth is expected for the coming year 6.7% failed
- Share count grows by less than 3% a year -0.5% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -2.0% failed
- Gross margin at 40% or higher and without meaningful erosion 56.6% failed
- Goodwill from acquisitions does not grow faster than revenue 4.2% failed
- Net debt below twice EBITDA 31 m net cash passed
- Operating cash flow covers the profits of the last three years 165 m passed
- Return on capital at 15% or higher, or up versus two years ago -6.6% failed
- Insiders hold at least 10% or are net buyers 6.0% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 1.4% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.05 | 1.05 – 1.05 | 122 | 854.6% | 1 |
| 12/31/2027 | 0.95 | 0.95 – 0.95 | 129 | -9.5% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.49 | – | -1 | -103.00 | – | 2 | 0 |
| 2025: Q1 | -0.34 | – | 26 | -35.40 | -18.60 | 0 | -3 |
| 2025: Q2 | -0.28 | – | 28 | -8.20 | -14.10 | 0 | -2 |
| 2025: Q3 | -0.16 | – | 28 | -28.20 | -8.40 | 7 | 5 |
| 2025: Q4 | 0.02 | – | 31 | – | 1.00 | 5 | 4 |
| 2026: Q1 | -0.37 | – | 30 | 13.20 | -17.10 | -5 | -6 |
| 2026: Q2 | 0.24 | 185.70 | 33 | 15.60 | 10.10 | -1 | -2 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 103 | 51 | 33 | 2.15 | 24 | 223 | 240 |
| 2017 | 113 | 46 | 32 | 2.11 | 41 | 263 | 283 |
| 2018 | 106 | 22 | 19 | 1.27 | 35 | 264 | 279 |
| 2019 | 115 | 34 | 27 | 1.89 | 37 | 288 | 331 |
| 2020 | 130 | -28 | -24 | -1.69 | 13 | 272 | 366 |
| 2021 | 148 | 3 | 4 | 0.28 | 8 | 287 | 348 |
| 2022 | 156 | -19 | -15 | -1.02 | 4 | 286 | 349 |
| 2023 | 121 | 1 | -83 | -5.64 | -2 | 212 | 271 |
| 2024 | 120 | -5 | -56 | -3.83 | 5 | 154 | 203 |
| 2025 | 113 | -11 | -11 | -0.76 | 11 | 143 | 190 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Anika Therapeutics, Inc. , a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
| Employees | 235 |
|---|---|
| Headquarters | Bedford, MA |
| Address | 32 Wiggins Avenue, 01730 Bedford, United States |
| Phone | 781 457 9000 |
| Website | anika.com |
| IPO Date | 29. Apr 1993 |
| ISIN | US0352551081 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Cheryl Renee Blanchard Ph.D. | Executive Chair | 1964 |
| Stephen D. Griffin | President, Principal Financial Officer, CEO & Director | 1986 |
| Ian W. McLeod | Senior VP, Chief Accounting Officer & Treasurer | 1966 |
| Matthew Hall | Executive Director of Corporate Development & Investor Relations | – |
| Lisa Funiciello | VP & Chief Human Resources Officer | – |
| Ben Joseph | Senior Vice President of Commercial | – |
| Mira Leiwant | Senior Vice President of Regulatory, Quality & Clinical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.